Senseonics has started an early human study of Freedom, an implanted glucose-monitoring system designed to communicate directly with a phone without an external transmitter. The study is testing safety and basic function; the company has not presented human performance results in its announcement. Freedom study announcement
For readers following continuous glucose monitors, the central change is the communication architecture. A sensor under the skin and a transmitter worn above it are different components.
Moving the battery and the radio
Freedom adds an internal battery and Bluetooth to the sensing approach used by Eversense 365. Senseonics describes the human work as early feasibility testing, including whether the direct communication link functions as intended.
That makes the first question more basic than a comparison of glucose accuracy. Can the proposed design work in people sufficiently well to inform a larger study? A successful radio link would answer part of that question, while leaving glucose performance and long-term use to their own evaluations.
The company also describes preclinical communication testing. Such engineering observations are preliminary support for a design choice, rather than human evidence that the finished system will deliver reliable measurements for a year.
Eversense’s clearance belongs to Eversense
The FDA record for Eversense 365 identifies that existing system and its 2024 substantial-equivalence decision. It is a separate device record from the investigational Freedom programme.
This distinction prevents an easy category error: a development can reuse an existing sensing principle while changing other parts that need evaluation. An established predecessor’s regulatory status does not make every planned successor available.
A one-year design ambition also differs from one year of observed human performance. The announcement does not supply that complete follow-up.
The dates are development targets
Senseonics expects a pivotal study in 2027 and targets a possible commercial launch in 2028. Both are forward-looking plans, dependent on subsequent work and review.
For now, the supported development is that human feasibility testing has begun. Claims about comparative accuracy, reduced treatment burden or suitability for an individual would need evidence beyond this announcement. The programme is interesting because it changes where sensing and transmission happen; the results will determine what that change can support.